| Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China. | |
| | |
MedLine Citation:
|
PMID: 20734318 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The aim of this Phase II study was to determine the efficacy and safety of combined bortezomib and thalidomide (VT) regime as initial treatment for newly diagnosed patients with multiple myeloma (MM) in China. Thirty-four patients have been enrolled in this study and were planned to receive VT regime up to eight 21-day cycles. Bortezomib (1.3 mg/m(2) ) was given intravenously on days 1, 4, 8, and 11, while oral thalidomide (100 mg/day) was given on days 1 to 21. The primary end point was clinical response; the secondary end point was safety. Among 34 patients enrolled, 26 patients were able to complete the planned eight cycles of therapy. After eight cycles, the overall response rate was 100% (complete response 31%; near-complete response 23%; partial response 42%; minimal response 4%). The best response occurred within the first four cycles in 96% of patients. Adverse events included hematologic (53%), peripheral neuropathy (38%), fatigue (35%), gastrointestinal (45%), and fever (32%). Grade 3 nonhematologic adverse events included four patients (12%) with renal failure associated with tumor lysis syndrome, one patient (3%) with peripheral sensory and motor neuropathy that improved with VT dose reduction, and one patient (3%) with hypotension. One patient (3%) experienced Grade 4 thrombocytopenia. No patient experienced deep venous thrombosis, while 1 patient (3%) died due to acute renal failure. In conclusion, Bortezomib in combination with thalidomide is a very effective regimen for newly diagnosed MM patients and the toxicities are manageable. |
| | |
Authors:
|
Shi-Lun Chen; Bin Jiang; Lu-Gui Qiu; Li Yu; Yu-Ping Zhong; Wen Gao |
Related Documents
:
|
9237028 - Safety of dobutamine stress echocardiography in 474 consecutive studies. 17636308 - Incidence of ventricular tachyarrhythmias during permanent pacemaker therapy in low-ris... 1383988 - Comparison of clinical benefits and outcome in patients with programmable and nonprogra... 9891948 - Diagnostic value of dobutamine echocardiography in patients with angina-like symptoms p... 19618008 - Thrombophilia-related genetic variations in patients with pulmonary embolism in the mai... 8688988 - Disposition kinetics of dibekacin in patients with renal failure and in patients underg... |
Publication Detail:
|
Type: Journal Article Date: 2010-08-23 |
Journal Detail:
|
Title: Anatomical record (Hoboken, N.J. : 2007) Volume: 293 ISSN: 1932-8494 ISO Abbreviation: Anat Rec (Hoboken) Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-11-08 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101292775 Medline TA: Anat Rec (Hoboken) Country: United States |
Other Details:
|
Languages: eng Pagination: 1679-84 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Wiley-Liss, Inc. |
Affiliation:
|
Department of Hematology and Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Demethylation of specific Wnt/?-catenin pathway genes and its upregulation in rat brain induced by p...
Next Document: A critical review of objective personality inventories with sex offenders.